OKYO Pharma Limited (OK10)

Overview

OKYO Pharma Limited stands out as a pivotal player in the realm of biopharmaceuticals, particularly focusing on the burgeoning field of inflammatory eye diseases and ocular pain management. Based in London, United Kingdom, this clinical-stage company has been committed since its inception in 2007 to the mission of addressing the unmet medical needs of patients grappling with these complex conditions. Through its dedication to innovation and research, OKYO Pharma Limited is pioneering the development of novel therapeutics designed to offer relief and improve the quality of life for individuals afflicted by these debilitating diseases.

Products and Services

• OK-101

  As the vanguard of OKYO Pharma Limited's portfolio, OK-101 is a trailblazing preclinical product candidate currently in Phase II clinical trials. Specifically engineered for the treatment of dry eye disease, a prevalent and often chronic condition that causes significant discomfort and visual disturbances, OK-101 encapsulates the company's focus on leveraging cutting-edge science to confront and mitigate ocular ailments. This pioneering therapy embodies their commitment to addressing the intricacies of eye-related health issues through innovative research and development.

• OK-201

  In its quest to diversify and deepen its therapeutic offerings, OKYO Pharma is also in the process of developing OK-201. This unique compound is a bovine adrenal medulla, lipidated-peptide preclinical analogue aimed at the treatment of neuropathic chronic pain. Understanding the intricate nexus between ocular conditions and neuropathic pain, the company is expanding its research horizons to encompass solutions that not only address eye diseases but also the chronic pain that can accompany or result from such conditions. OK-201 represents a significant stride towards achieving holistic management options for patients suffering from a broad spectrum of debilitating symptoms.